Statement Of Investor Complaints For Quarter Ended March , 2017

Statement of investor complaints for quarter ended 31st March, 2017 Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the statement of investor complaints of GlaxoSmithKline Pharmaceuticals Limited for the quarter ended 31st March, 2017. Particulars No of complaints Complaints pending as on 1st January, 2017. 02 Complaints received during 1st January to 31st March, 2017 56 Complaints resolved during 1st January to 31st March, 2017 58 Complaints pending as on 31st March, 2017. NIL

Pdf Link: Statement Of Investor Complaints For Quarter Ended March , 2017

Source : BSE - www.bseindia.com

Published on April 07, 2017
TOPICS

Related

This article is closed for comments.
Please Email the Editor